Indiana University School Of Optometry
Doctorate of Optometry

Indiana University College of Arts and Science
Bachelor of Art, Chemistry

• Prospective randomized study to determine whether use of Rhopressa™ accelerates corneal clearing after removal of Descemet membrane for treatment of Fuchs dystrophy, Cornea Research Foundation of America/Price Vision Group,  2019/Active
• Randomized Comparison of Standard vs Accelerated Corneal Cross Linking for Treatment of Progressive Keratoconus or Ectasia, Cornea Research Foundation of America/Price Vision Group,  2019/Active
• A randomized, double-masked, placebo-controlled study of the safety of Amphotericin 0.255 μg/mL in Optisol-GS, Price Vision Group/Cornea Research Foundation of America, 2019/Active
• Sub-Investigator. A multi-center, double-masked, randomized, placebo-controlled study of the efficacy and safety of HY02 ointment in subjects with inflamed Meibomian gland dysfunction.  Hovione Scientia, 2019/Active.
• A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants with Presbyopia, Allergan, 2018/Active.
• Phase 3, double-masked, randomized, controlled study of KPI-121 0.25% Ophthalmic suspension compared to vehicle in subjects with dry eye disease (Stride 3), Kala, 2018/Active
• Genetic susceptibility to contact lens related microbial keratitis. University Hospitals Cleveland Medical Center/2018/Active.
• Effect of TrueTear use on anterior corneal surface imaging quality. Price Vision Group. 2018/Active.
• Randomized, double-masked, placebo-controlled evaluation of netarsudil for prevention of corticosteroid-induced intraocular pressure elevation. Cornea Research Foundation of America 2017/Active.
• Discovery approach to ocular hypertension. National Institutes of Health, 2017/Active.
• Investigator. A double-masked, randomized, multi-center Phase 2 study to evaluate the efficacy and safety of LacripepTM in subjects with dry eye associated with primary Sjogren’s syndrome. TearSolutions, Inc. 2017/Active.
• Randomized, double-masked, placebo-controlled evaluation of netarsudil for prevention of corticosteroid-induced intraocular pressure elevation. Cornea Research Foundation of America 2017/Active.
• A Phase 3, Double-Masked, Randomized. Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease, Kala,2016/2018
• A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients With Presbyopia, Allergan,2016/2017
• A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca , Auven/2016
• A Multi-Center, Open-Label, Parallel-Arm, Randomized, Dose Ranging Study of ENV515 (travoprost) Intracameral Implant in Subjects with Bilateral Ocular Hypertension or Early Primary Open Angle Glaucoma, Envisia Therapeutics, Inc./2015
• A randomized, masked, active placebo-controlled phase 1 study of Amnion-derived Cellular Cytokine Solution (ACCS) eye drops in the treatment of Dry Eye, Stemnion, Inc./2015
• Sub-Investigator – A Phase 3, Multicenter, Randomized, Double-masked, and Placebo controlled Study Evaluating the Efficacy and Safety of a 5.0%Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease and History of Recent Artificial Tear Use (OPUS-3), Shire Development LLC/2015.
• Sub-Investigator – Dry eye assessment and management (DREAM) study IND # 106,387. The University of Pennsylvania 2014/Active.
• Sub-Investigator, A Phase III double-masked, randomized, controlled trial of KPI-121 in postsurtical inflammation. Kala Pharmaceuticals, Ind. 2014/Active.
• Sub-Investigator – KPI-121-C-002: A Phase 2, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease. Kala Pharmaceuticals, Inc. 2014/Active.
• Sub-Investigator – A multi-center, double-masked, randomized, controlled, efficacy and safety study of EBI-005 mg/mL topical ophthalmic solution versus vehicle control in subjects with moderate to severe dry eye disease (DED). Eleven Biotherapeutics 2014/Active.
• Sub-Investigator A multi-center, randomized, placebo-controlled evaluation of the safety and efficacy of the KXL system with VibeX (riboflavin ophthalmic solution) for corneal collagen cross-linking in eyes with keratoconus. Protocol KXL-005. Avedro 2013/Active.
• Sub-Investigator – A Phase 3, Multicenter, Randomized, Double–Masked and Placebo–Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Currently Using Artificial Tears (OPUS-2) Shire/2013.
• Sub-Investigator – A multi-center, randomized, placebo-controlled evaluation of the safety and efficacy of the KXL system with VibeX (riboflavin ophthalmic solution) for corneal collagen cross-linking in eyes with keratoconus. Protocol KXL-002. Avedro 2012/Active.
• Sub-Investigator – Prospective study of the incidence of graft rejection episodes and intraocular pressure elevation in the second year after Descemet membrane endothelial keratoplasty. Cornea Research Foundation of America 2012/Active.
• Sub-Investigator – Comparison of two corticosteroid-dosing regimens for prevention of corneal transplant rejection episodes after Descemet’s membrane endothelial keratoplasty. Cornea Research Foundation of America 2011/2013.
• Sub-Investigator – A prospective, double-masked, placebo controlled comparison of topical 0.15% ganciclovir gel (Zirgan) versus 0.3% hypromellose gel (Genteal gel; placebo) for the treatment of adenovirus conjunctivitis. Lifelong Vision Foundation 2011/2012.
• Sub-Investigator – Evaluation of the Epiglare tester for the measurement of glare-induced changes in best spectacle corrected visual acuity in subjects with and without cataracts. Epico LLC 2011/2012.
• Sub-Investigator – Characterization of the protein content of aqueous humor as related to cornea transplant survival. Cornea Research Foundation of America 2011/Active.
• Sub-Investigator – A Comparison of Three Endothelial Microscopy Techniques. Cornea Research Foundation of America 2011.
• Sub-Investigator – Efficacy and Safety of Bromfenac Ophthalmic Solution vs. Placebo for The Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery. ISTA 2011.
• Sub-Investigator – A randomized, prospective, double masked clinical trial of Life 4°C vs. Optisol GS corneal storage media. Numedis, Inc. 2011/2012.
• Sub-Investigator – Survey study comparing contact lenses and LASIK for vision correction. Cornea Research Foundation of America 2010/Active.
• Sub-Investigator – A multi-center, double-masked, randomized, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of 0.005% and 0.010% aqueous cyclosporine ophthalmic solutions administered twice daily for at least two weeks prior to and six months after LASIK surgery in reducing post-LASIK corneal hypoesthesia. Allergan 2010/2011.
• Sub-Investigator – Evaluation of Corneal Cross Linking for Treatment of Corneal Edema. Cornea Research Foundation of America. 2010/2011.
• Sub-Investigator – Evaluation of two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus or Ectasia. Cornea Research Foundation of America. 2010/Active.
• Sub-Investigator – Clinical Protocol for the Treatment of Corticosteroid Induced Intra-ocular Pressure Increases After Corneal Transplantation. Francis Price, MD.  2009/2010.
• Sub-Investigator – A Prospective Evaluation of Treatment Duration of the UVX^TM System for treating infectious keratitis. Cornea Research Foundation of America. 2009/2013.
• Sub-Investigator – A prospective multi-center clinical study to evaluate the safety and effectiveness of the light adjustable lens (LAL) in subjects undergoing cataract extraction. Calhoun Vision, Inc. 2009/Present. A Multi-Center, Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the Effects of diquafosol tetrasodium Ophthalmic Solution, 2% in Subjects with Dry Eye Disease and a Central Corneal Staining Score of 3 (NEI Scale). Inspire Pharmaceuticals, Inc. 2009/2013.
• Sub-Investigator – Efficacy and safety of bromfenac ophthalmic solution QD vs. placebo QD for treatment of ocular inflammation and pain associated with cataract surgery. ISTA Pharmaceuticals, Inc. 2009.
• Sub-Investigator – A prospective study of Staar ICL metrics. Cornea Research Foundation of America – 2008/2009.
• Sub-Investigator – A randomized, observer-masked, parallel-group, multicenter trial evaluating the ocular penetration of 1.5% levofloxacin ophthalmic solution and 0.5% moxifloxacin ophthalmic solution in subjects undergoing corneal transplant surgery. Vistakon Pharmaceuticals, LLC – 2008/2009.
• Sub-Investigator – Open-enrollment, prospective study of endothelial keratoplasty outcomes. Cornea Research Foundation of America – 2008/Active.
• Sub-Investigator – Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus. Peschke Meditrade GmbH – 2008/2010.
• Sub-Investigator – Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Corneal Ectasia after Refractive Surgery. Peschke Meditrade GmbH – 2008/2010.
• Sub-Investigator – Characterization of the protein content of aqueous humor. Cornea Research Foundation of America 2008/2013.
• Sub-Investigator – Surveillance of resistance to formulations of antimicrobials in cultures of the eye. Allergan, Inc. 2007/2008.
• Sub-Investigator – A Multi Center, Double Masked, Randomized Parallel Group Study Evaluating the Safety and Efficacy of a New Formulation of Ketorolac Tromethamine 0.45% Ophthalmic Solution Compared with Vehicle Administered Preoperatively and Twice-Daily Postoperatively for Two Weeks for the Treatment of Anterior Segment Inflammation, Pain, and Inhibition of Surgically Induced Miosis Following Cataract Extraction with Posterior Chamber Intraocular Lens (IOL) Implantation. Allergan, Inc. 2007.
• Sub-Investigator – A prospective, randomized, multicenter center study evaluating the use of intraocular dexamethasone in conjunction with Descemet’s stripping and endothelial keratoplasty, a type of cornea transplant. Cornea Research Foundation of America and Ophthalmic Consultants of Long Island – 2007/2008.
• Sub-Investigator – Intraocular Pressure after Descemet’s stripping endothelial keratoplasty as measured by contour matching tonometry and applanation tonometry. Cornea Research Foundation of America – 2007.
• Sub-Investigator – Clinical evaluation of the safety and effectiveness of the Veriflex anterior chamber phakic IOL for the correction of myopia. Advanced Medical Optics – 2007/Active.
• Sub-Investigator – A multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study to assess the efficacy and safety of LX201 implantation for the prevention of corneal allograft rejection episodes or graft failure in subjects who have experienced one or more rejection episodes following penetrating keratoplasty. Lux Biosciences – 2007/2010.
• Sub-Investigator – A multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study to assess the efficacy and safety of LX201 for the prevention of allograft rejection episodes and graft failure following penetrating keratoplasty with LX201 implantation in subjects who are at increased immunological risk. Lux Biosciences – 2007/2010.
• Sub-Investigator – A prospective, multi-center feasibility trial to evaluate the safety and effectiveness of the IntraLase FS laser used to harvest donor tissue for Descemet’s stripping with endothelial keratoplasty.  IntraLase Corp. – 2007/2008.
• Sub-Investigator – A Randomized Evaluation of Two Surgical Kits: Gatifloxacin, Ketorolac LS, and Pred Forte Compared with Moxifloxacin, Nepafenac, and EconoPred in Patients Undergoing Cataract Surgery. William Trattler, MD – 2006.
• Sub-Investigator – Comparative Study of Corneal Transplant Survival and Endothelial Cell Loss following Descemet Stripping Automated Endothelial Keratoplasty vs. Penetrating Keratoplasty. Case Vision Research Coordinating Center – 2006/2011.
• Sub-Investigator – FECD Genetics Multi-Center Study.  Case Vision Research Coordinating Center – 2006/2011.
• Sub-Investigator – A prospective, randomized, single center study evaluating use of surgeon- and eye bank-prepared donor tissue for Descemet’s stripping and endothelial keratoplasty, a type of cornea transplant.  Protocol 2005-10. Cornea Research Foundation of America and the North Carolina Eye Bank, Inc. – 2006/2007.
• Sub-Investigator – A prospective, multi-center feasibility trial to evaluate the IntraLase FS laser used for penetrating keratoplasty.  Protocol FMTO-007-ITK.  IntraLase Corp. – 2005/2006.
• Sub-Investigator – Randomized, controlled, multicenter comparative trial to evaluate the SOLX Gold Shunt for the reduction of intraocular pressure (IOP) in glaucomatous eyes following failed medical and conventional surgical treatments.  Protocol SLX53.  SOLX – 2005/2014.
• Sub-Investigator – A masked comparison of Acular LS plus steroid versus steroid alone for the prevention of macular leakage in cataract patients.  Protocol. John Wittpenn, MD – 2005/2006.
• Sub-Investigator – Comparison of healing response of the corneal wound created by blade or femtosecond laser, in presence of implanted hydrogel sponge.  Protocol 2902. CooperVision – 2005.
• Sub-Investigator – A multi-center, double-masked, randomized, placebo controlled, evaluation of the onset and duration of action of R89674 0.25% ophthalmic solution in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.  Protocol 05-003-11.  Vistakon Pharmaceuticals, LLC – 2005/2006.
• Sub-Investigator – A study to determine whether early corneal protein changes associated with keratoconus can be identified through 2-dimensional gel electrophoresis and mass spectrometric analysis of human tear samples.  Protocol: K-10-03-001.  Cornea Research Foundation of America – 2004/2006.
• Sub-Investigator – A prospective, randomized, single-center clinical trial to evaluate the use of orbital seal sunglasses after LASIK.  Protocol 2004-20.  Panoptx – 2004/2005.
• Sub-Investigator – A prospective, randomized, multi-center clinical comparison of fellow eyes undergoing LASIK with either a mechanical keratome or IntraLase FS laser.  Protocol PRIM-016-CST.  IntraLase Corp – 2004/2005.
• Sub-Investigator – A prospective, single-center feasibility trial to evaluate the safety and effectiveness of the IntraLase FS laser used for corneal endostromal tissue harvesting.  Protocol FMTO-006-ITK.  IntraLase Corp – 2004/2006.
• Sub-Investigator – Clinical study of implantation of a UV-absorbing acrylic posterior chamber intraocular lens.  Protocol 2003-A101.  Hoya Holdings, Inc. – 2004/2006.
• Sub-Investigator – A study to determine if Restasis^TM (cyclosporin 0.05% ophthalmic solution) is effective, either alone or in combination with pulsed dosing of corticosteroids, for prevention of graft rejection episodes after corneal transplantation.  Protocol R-09-03-002.
• Price Vision Group – 2003/2005.
• Sub-Investigator – A prospective, randomized, double-masked study to evaluate whether pre-operative dosing with Acular LS is effective for maintaining pupil dilation and for mitigating pain and inflammation during and after cataract surgery.  Protocol A-09-03-001.
• Price Vision Group – 2003/2004.
• Sub-Investigator – A Study to Compare the Effect of Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions on Corneal Epithelial cell health following two dosing regimens.  Protocol 08-03-001.  Price Vision Group – 2003.
• Sub-Investigator – A comparison of the duration of IOP control with travopost, bimatoprost, and latanoprost in patients with glaucoma and ocular hypertension: a multicenter, randomized, masked-evaluator, parallel group study.  Protocol 03-005-03. Ophthalmic Research Associates – 2003.
• Sub-Investigator – To evaluate the effect of gatifloxacin 0.3% ophthalmic solution on corneal endothelial cell counts in two subpopulations:  non-surgical, normal healthy volunteers and healthy volunteers scheduled to undergo standard cataract surgery.  Protocol PIND-GATI-004.  Allergan – 2003.
• Sub-Investigator – A comparative study of olopatadine QD versus vehicle in patients with seasonal allergic conjunctivitis or rhinoconjunctivitis.  Protocol C-02-67.  Alcon – 2003.
• Sub-Investigator – A Phase III prospective randomized controlled clinical trial to investigate the simultaneous versus sequential surgical correction of myopia and astigmatism with laser in situ keratomileusis.  Protocol EXKM-800.  Corneal Consultants of Indiana – 1996
• Sub-Investigator  – A Phase III prospective randomized controlled clinical trial to investigate the use versus non-use of topical corticosteroids on the stability of the manifest refraction after the surgical correction of myopia and astigmatism with laser in situ keratomileusis. Protocol EXKM-801. Corneal Consultants of Indiana – 1997/2000
• Sub-Investigator – A Multi-Center Prospective Clinical Study to Evaluate the Use of LADARVision System in Correction of Hyperopia and Astigmatism. Protocol 7201-0010. Autonomous Technologies Corporation – 1998/1999
• Sub-Investigator – A Multi-Center Prospective Clinical Study to Evaluate the Use of the LADARVision Excimer Laser System in LASIK Correction of Hyperopia and Astigmatism. Protocol 7201-0022. Autonomous Technologies Corporation – 1998/2000
• Sub-Investigator – US Clinical Study of the Artisan Myopia Lens for the Correction of High Myopia in Phakic Eyes. Ophtec USA, Inc. – 1998/2003
• Sub-Investigator – The Cornea Donor Study: A prospective cohort study to determine whether the graft-failure rate over a 5-year follow-up period is equivalent with corneal tissue from donors older than 65 years of age compared with that from younger donors.  Two other specific objectives also evaluated.  Protocol Version 1.0- Jaeb Center for Health Research – 1999/2014
• Sub-Investigator – Multicenter Clinical Study of the OCULAID Endocapsular Tension Ring (CTR) and OPERAID Tension Ring Inserter.  FDA IDE Number: G010064.  Protocol CTR 275/276. OPHTEC USA, Inc.– 2001/2004
• Sub-Investigator – Multicenter Clinical Study of the Ophthec Model 311 Iris Reconstruction Lens.  FDA IDE Number: G020127 and G020127/A001.  OPHTEC USA, Inc. – 2002/Active